1Schwarzer R,Schnell-Inderst P,Grabein K,et al.Prognostic value and clinical effectiveness of high sensitivity C-reactive protein as a marker in primary prevention of major cardiac events[J].Z Evid Fortbild Qual Gesundhwes,2009,103(6):319-329.
5Buckley DI,Fu R,Freeman M,et al.C-reactive protein as a risk factor for coronary heart disease:a systematic review and meta-analyses for the US Preventive Services Task Force[J].Ann Intern Med,2009,151(7):483-495.
4SEINO Y, IKEDA M, Y MAMATO K, et al. Interleukin-6 gene transcripts are expressed in human ath- erosclerotic lesion [J]. Cytokine, 1994,26 : 141 - 145.
5MIZIA-STEC K, GASIOR Z, ZAHORSKA-MARKIEWICZ B, et al. Serum tumor necrosis factor [alpha], interleukin-2 and interleukin-10 activation in stable angina and acute coronary syndromes [J]. Coron Artery Dis, 2003,14: 431-438.
6KOCH W, KASTRATI A, BOTTIGER C, et al. Interleukin-10 and turner necrosis factor gene polymorphisms and risk of coronary artery disease and myocardial infarction [J]. Atherosclerosis, 2001,159 : 137 -144.
7JENNYNS, TRACYRP, OGGMS, et al. In the elderly, interleukin-6 plasma levels and the 174G>C polymorphism are associated with the development of cardiovascular disease [J]. Arterioscler Thromb Vase Boil,2002,22 : 2066-2071.
8Boos C J, Lip G Y. Is Hypertension an Inflammatory Process? [J]. Curr Pharm Des,2006,12(13):1623-1635.
9Okamura H, Nagata K, Komatsu T, et al. A Novel Costimulatory Factor for Gamma Interferon Induction Found in the Livers of Mice Causes Endotoxie Shock[J]. Infect Immun, 1995 63 (10) :3966-3972.
10Ushio S,Namba M,Okura T,et al. Cloning of the cDNA for Human IFN-gamrna Inducing Factor, Expression in Escherichiacoli,and Studies on the Biologic-activities of the Protein[J]. J Immunol, 1996,156 (11) : 4274-4279.
2Li JJ, Fang CH. C-reactive protein is not only an inflammatorymarker but also a direct cause of cardiovascular disease[j]. MedHypotheses, 2004, 62(4): 499-506.
4Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemicatherosclerosis: a comparison of C-reactive protein, fibrinogen,homocysteine, lipoprotein(a), and standard cholesterol screeningas predictors of peripheral arterial disease[j]. JAMA, 2001,285(19): 2481-2485.
5Ridker PM. C-reactive protein and the prediction ofcardiovascular events among those at intermediate risk[j]. J AmColl Cardiol, 2007, 49(21): 2129-2138.
6Laaksonen DE, Niskanen L, Nyyssonen K, et al. C-reactiveprotein and the development of the metabolic syndrome anddiabetes in middle-aged men[j], Diabetologia, 2004, 47(8):1403-1410.
7Alberti KG, Zimmet P, Shaw J, et al. The metabolic syndrome—anew worldwide definition[j]. Lancet, 2005, 366(9491): 1059-1062.
8Kahn HS. The lipid accumulation product is better than BMIfor identifying diabetes: a population-based comparison[j].Diabetes Care, 2006, 29(1): 151-153.
9Taverna MJ, Martinez-Larrad MT, Frechtel GD; et al. Lipidaccumulation product: a powerful marker of metabolic syndromein healthy population[j]. EurJ Endocrinol; 2011; 164(4): 559-567.
10Kahn HS. The "lipid accumulation product” performs betterthan the body mass index for recognizing cardiovascular risk:a population-based comparison[j]. BMC Cardiovasc Disord,2005,5:26.
